Oaktree Acquisition Corp. III Life Sciences
Price Action
Technical Summary
STAGE 2 UPTRENDOaktree Acquisition Corp. III Life Sciences is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is weak (RS Rating: 47), showing significant lag compared to the market leaders. Earnings growth of 2957% provides fundamental context to the price action. Momentum will need to be maintained above the 50-day moving average to sustain this leadership phase.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $10.68 | -0.07% | BELOW |
| 50 SMA | $10.66 | +0.12% | ABOVE |
| 100 SMA | $10.65 | +0.15% | ABOVE |
| 150 SMA | $10.64 | +0.33% | ABOVE |
| 200 SMA | $10.61 | +0.61% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is OACC in an uptrend right now?
OACC has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, OACC is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is OACC overbought or oversold?
OACC's RSI (14) is 53. The stock is in neutral territory, neither overbought nor oversold.
Is OACC outperforming the market?
OACC has a Relative Strength (RS) Rating of 47 out of 99. OACC is currently lagging the broader market.
Where is OACC in its 52-week range?
OACC is trading at $10.67, which is 99% of its 52-week high ($10.75) and 82% above its 52-week low ($10.30).
How volatile is OACC?
OACC has a Beta of 0.09 and 52-week volatility of 6%. It's less volatile than the S&P 500 - generally more stable.